A first-in-kind MAPK13 inhibitor corrects stem cell reprogramming and muco-obstructive lung disease
Yong Zhang, Kangyun Wu, Dailing Mao, Courtney A. Iberg, Huiqing Yin‐Declue, Kelly Sun, Hallie A. Wikfors, Shamus P. Keeler, Ming Li, Deanna Young, Jennifer Yantis, Erika C. Crouch, Joshua R. Chartock, Zhenfu Han, Kay O. Broschat, , Michael J. Holtzman
The paper identifies a first-in-kind MAPK13 inhibitor that corrects stem cell reprogramming and reduces muco-obstructive lung disease symptoms in mice.
bioRxiv · Aug 21, 2024 · PreprintImmunology